Home › Compare › BCDAW vs MRK

BCDAW vs MRK: Dividend Comparison 2026

BCDAW yields 32786.89% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BCDAW wins by $7.149378406802545e+21M in total portfolio value
10 years
BCDAW
BCDAW
● Live price
32786.89%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.149378406802545e+21M
Annual income
$7,106,739,309,572,423,000,000,000,000.00
Full BCDAW calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — BCDAW vs MRK

📍 BCDAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCDAWMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCDAW + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BCDAW pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCDAW
Annual income on $10K today (after 15% tax)
$2,786,885.25/yr
After 10yr DRIP, annual income (after tax)
$6,040,728,413,136,559,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, BCDAW beats the other by $6,040,728,413,136,559,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCDAW + MRK for your $10,000?

BCDAW: 50%MRK: 50%
100% MRK50/50100% BCDAW
Portfolio after 10yr
$3.5746892034012726e+21M
Annual income
$3,553,369,654,786,211,600,000,000,000.00/yr
Blended yield
99.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BCDAW
No analyst data
Altman Z
-75.0
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCDAW buys
0
MRK buys
0
No recent congressional trades found for BCDAW or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCDAWMRK
Forward yield32786.89% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$7.149378406802545e+21M$56.8K ✓
Annual income after 10y$7,106,739,309,572,423,000,000,000,000.00 ✓$9,798.13
Total dividends collected$7.146574325368343e+21M$28.9K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BCDAW vs MRK ($10,000, DRIP)

YearBCDAW PortfolioBCDAW Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$3,289,389$3,278,688.52$11,206$366.19+$3.28M → BCDAW
2$1,011,452,394$1,007,932,748.46$12,650$502.35+$1011.44M → BCDAW
3$290,735,268,121$289,653,014,059.08$14,407$694.19+$290735.25M → BCDAW
4$78,123,080,869,461$77,811,994,132,571.95$16,585$967.82+$78123080.85M → BCDAW
5$19,624,484,924,633,140$19,540,893,228,102,816.00$19,342$1,363.89+$19624484924.61M → BCDAW
6$4,608,534,766,328,053,000$4,587,536,567,458,695,700.00$22,913$1,947.19+$4608534766328.03M → BCDAW
7$1,011,770,904,242,838,300,000$1,006,839,772,042,867,400,000.00$27,662$2,823.89+$1011770904242838.25M → BCDAW
8$207,666,224,199,856,750,000,000$206,583,629,332,316,930,000,000.00$34,159$4,173.35+$207666224199856768.00M → BCDAW
9$39,849,623,579,553,230,000,000,000$39,627,420,719,659,375,000,000,000.00$43,337$6,308.80+$39849623579553226752.00M → BCDAW
10$7,149,378,406,802,546,000,000,000,000$7,106,739,309,572,423,000,000,000,000.00$56,776$9,798.13+$7.149378406802545e+21M → BCDAW

BCDAW vs MRK: Complete Analysis 2026

BCDAW — Stock

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Full BCDAW Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BCDAW vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCDAW vs SCHDBCDAW vs JEPIBCDAW vs OBCDAW vs KOBCDAW vs MAINBCDAW vs JNJBCDAW vs ABBVBCDAW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.